

Supplementary File for: An imperfect tool:
COVID-19 ‘test & trace’ success relies on
minimising the impact of false negatives and
continuation of physical distancing.

Emma L. Davis^{1,+,*}, Tim C. D. Lucas^{1,+}, Anna Borlase¹,
Timothy M Pollington^{1,3}, Sam Abbott², Diepreye Ayabina¹,
Thomas Crellen¹, Joel Hellewell², Li Pi¹, CMMID COVID-19
working group¹, Graham F. Medley⁴, T. Déirdre
Hollingsworth^{1,†}, and Petra Klepac^{2,5,†}

¹Big Data Institute, University of Oxford, UK.

²Department of Infectious Disease Epidemiology, London
School of Hygiene and Tropical Medicine, UK.

³MathSys CDT, University of Warwick, UK.

⁴Centre for Mathematical Modelling of Infectious Disease,
London School of Hygiene and Tropical Medicine, London, UK.

⁵Department for Applied Mathematics and Theoretical
Physics, University of Cambridge, UK.

*Corresponding author

+,[†]Contributed equally

1 Additional figures




Figure S1: **Comparing testing procedures.** Comparing utility of test-and-release of negative-testing cases (left-hand panels) with maintaining isolation of cases for a minimum of 7 days (right-hand panels) given assumed test sensitivities of 65% or 95%, and compared to no-testing. R_S is assumed to be 1-3. Error bars: 95% confidence intervals calculated from simulation output variation.

2 CMMID working group authorship list

3 The following authors were part of the Centre for Mathematical Modelling of
4 Infectious Disease 2019-nCoV working group. Each contributed in process-
5 ing, cleaning and interpretation of data, interpreted findings, contributed

6 to the manuscript, and approved the work for publication: Alicia Rosello,
7 Rosalind M Eggo, Quentin J Leclerc, Matthew Quaife, Emily S Nightin-
8 gale, Thibaut Jombart, Jon C Emery, Timothy W Russell, Nikos I Bosse,
9 Megan Auzenbergs, Amy Gimma, Charlie Diamond, Yang Liu, Kiesha Prem,
10 Eleanor M Rees, Christopher I Jarvis, W John Edmunds, Akira Endo, David
11 Simons, Billy J Quilty, Damien C Tully, Oliver Brady, C Julian Villabona-
12 Arenas, Gwenan M Knight, Samuel Clifford, Stéphane Hué, Kevin van Zand-
13 voort, Adam J Kucharski, Mark Jit, Arminder K Deol, Kathleen O'Reilly,
14 Anna M Foss, Fiona Yueqian Sun, James D Munday, Hamish P Gibbs, Rein
15 M G J Houben, Rachel Lowe, Sophie R Meakin, Georgia R Gore-Langton,
16 Sebastian Funk, Carl A B Pearson, Katherine E. Atkins, Simon R Procter,
17 Stefan Flasche, Nicholas G. Davies.

18 The following funding sources are acknowledged as providing funding
19 for the working group authors. Alan Turing Institute (AE). BBSRC LIDP
20 (BB/M009513/1: DS). This research was partly funded by the Bill & Melinda
21 Gates Foundation (INV-003174: KP, MJ, YL; NTD Modelling Consortium
22 OPP1184344: CABP; OPP1180644: SRP; OPP1183986: ESN; OPP1191821:
23 KO'R, MA). DFID/Wellcome Trust (Epidemic Preparedness Coronavirus re-
24 search programme 221303/Z/20/Z: CABP, KvZ). Elrha R2HC/UK DFID/
25 Wellcome Trust/This research was partly funded by the National Institute
26 for Health Research (NIHR) using UK aid from the UK Government to sup-
27 port global health research. The views expressed in this publication are
28 those of the author(s) and not necessarily those of the NIHR or the UK De-
29 partment of Health and Social Care (KvZ). ERC Starting Grant (#757688:
30 CJVA, KEA; #757699: JCE, MQ, RMGJH). This project has received fund-
31 ing from the European Union's Horizon 2020 research and innovation pro-
32 gramme - project EpiPose (101003688: KP, MJ, WJE, YL). This research
33 was partly funded by the Global Challenges Research Fund (GCRF) project
34 'RECAP' managed through RCUK and ESRC (ES/P010873/1: AG, CIJ,
35 TJ). HDR UK (MR/S003975/1: RME). Nakajima Foundation (AE). NIHR
36 (16/137/109: BJQ, CD, FYS, MJ, YL; Health Protection Research Unit for
37 Modelling Methodology HPRU-2012-10096: NGD, TJ; PR-OD-1017-20002:
38 AR). Royal Society (Dorothy Hodgkin Fellowship: RL). UK DHSC/UK
39 Aid/NIHR (ITCRZ 03010: HPG). UK MRC (LID DTP MR/N013638/1:
40 EMR, GRGL, QJL; MC_PC 19065: RME; MR/P014658/1: GMK). Au-
41 thors of this research receive funding from UK Public Health Rapid Support
42 Team funded by the United Kingdom Department of Health and Social Care
43 (TJ). Wellcome Trust (206250/Z/17/Z: AJK, TWR; 206471/Z/17/Z: OJB;

⁴⁴ 208812/Z/17/Z: SC, SFlasche; 210758/Z/18/Z: JDM, NIB, SFunk, SRM).

⁴⁵ No funding (AKD, AMF, DCT, SH).